RFK Jr. proposes FDA look the other way on unproven peptides, report says

Under the leadership of Health Secretary Robert F. Kennedy Jr., the FDA is reportedly developing an 'Interim Access Policy' that would allow for greater access to unproven peptide drugs. These substances, which are popular within the 'Make America Healthy Again' movement, have not been sufficiently vetted by FDA scientists for safety or efficacy. According to reports, the proposed policy would grant the agency 'enforcement discretion,' effectively signaling to specialty pharmacies that they will not face regulatory action for producing these unstudied compounds. While the Department of Health and Human Services has not yet provided an official comment, the move has raised concerns among experts regarding potential public health risks. The policy, currently under review by the White House, marks a significant shift in how the FDA handles substances that lack rigorous clinical backing, prioritizing broader access over traditional regulatory oversight protocols.